par Hoskins, P;Vergote, Ignace;Cervantes, Andrés;Tu, Dongsheng;Stuart, G;Zola, Paolo;Poveda, Andrés;Provencher, D;Katsaros, D;Ojeda, B;Ghatage, P;Grimshaw, Rachel;Casado, M.;Elit, L;Mendiola, César;Sugimoto, A;D'Hondt, Veronique ;Ozaita, Andrés;Germa, J R;Roy, M;Brotto, L;Chen, Dan;Eisenhauer, Elizabeth
Référence Journal of the National Cancer Institute, 102, 20, page (1547-1556)
Publication Publié, 2010-10
Référence Journal of the National Cancer Institute, 102, 20, page (1547-1556)
Publication Publié, 2010-10
Article révisé par les pairs
Résumé : | Topotecan has single-agent activity in recurrent ovarian cancer. It was evaluated in a novel combination compared with standard frontline therapy. |